Adenosine N1-oxide
Based on 1 Customer Validation
Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.50%
- CAS. Nr.: 146-92-9
- Formel: C10H13N5O5
- Molecular Weight:283.24
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Adenosine N1-oxide )(1-40 μM, 24 h) inhibits TNF-α and IL-6 secretion by RAW264.7 cells stimulated with 2 µg/mL LPS (HY-D1056)[2].
Adenosine N1-oxide )(20/100 μM, 30 mins) increases intracellular cAMP production in both peritoneal macrophages and RAW264.7 cells in a dose-dependent manner[2].
Adenosine N1-oxide )(5-10 μM, 30 mins) increases the protein level of phosphorylation of Akt and GSK-3β in 2 µg/mL LPS (HY-D1056)-stimulated RAW264.7 cells[2].
Adenosine N1-oxide )(2-10 μM, 6-7 days) promotes osteogenic and adipocyte differentiation in MC3T3-E1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells
-
Concentration:2, 5 and 10 μM
-
Incubation Time:30 mins
-
Result:Increased the protein level of phosphorylation of Akt and GSK-3β in 2 µg/mL LPS (HY-D1056)-stimulated RAW264.7 cells.
-
Cell Line:MC3T3-E1 cells
-
Concentration:2, 5 and 10 μM
-
Incubation Time:6-7 days
-
Result:Promoted osteogenic and adipocyte differentiation in MC3T3-E1 cells
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-induced endotoxin shock in BALB/c mice[1]
-
Dosage:135 mg/kg for three times
-
Administration:Oral administration
-
Result:Reduced the lethality caused by LPS (HY-D1056)-induced endotoxin shock in BALB/c mice.
Chemical Information
-
CAS. Nr. 146-92-9
-
Appearance Solid
-
Molecular Weight 283.24
-
Formel C10H13N5O5
-
Color White to off-white
-
SMILES
OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N(C=N2)C3=C2C(N)=[N+]([O-])C=N3)O1
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (176.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kohno K, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015;12(1):2. Published 2015 Jan 20. [Content Brief]
[2]. Ohashi E, et al. Adenosine N1-Oxide Exerts Anti-inflammatory Effects through the PI3K/Akt/GSK-3β Signaling Pathway and Promotes Osteogenic and Adipocyte Differentiation. Biol Pharm Bull. 2019;42(6):968-976. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5306 mL | 17.6529 mL | 35.3057 mL | 88.2644 mL |
| 5 mM | 0.7061 mL | 3.5306 mL | 7.0611 mL | 17.6529 mL | |
| 10 mM | 0.3531 mL | 1.7653 mL | 3.5306 mL | 8.8264 mL | |
| 15 mM | 0.2354 mL | 1.1769 mL | 2.3537 mL | 5.8843 mL | |
| 20 mM | 0.1765 mL | 0.8826 mL | 1.7653 mL | 4.4132 mL | |
| 25 mM | 0.1412 mL | 0.7061 mL | 1.4122 mL | 3.5306 mL | |
| 30 mM | 0.1177 mL | 0.5884 mL | 1.1769 mL | 2.9421 mL | |
| 40 mM | 0.0883 mL | 0.4413 mL | 0.8826 mL | 2.2066 mL | |
| 50 mM | 0.0706 mL | 0.3531 mL | 0.7061 mL | 1.7653 mL | |
| 60 mM | 0.0588 mL | 0.2942 mL | 0.5884 mL | 1.4711 mL | |
| 80 mM | 0.0441 mL | 0.2207 mL | 0.4413 mL | 1.1033 mL | |
| 100 mM | 0.0353 mL | 0.1765 mL | 0.3531 mL | 0.8826 mL |